Editorial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Orthop. Sep 18, 2024; 15(9): 831-835
Published online Sep 18, 2024. doi: 10.5312/wjo.v15.i9.831
Evolution of treatment options for juvenile idiopathic arthritis
Tao Ren, Jia-Hui Guan, Yu Li, Nan-Nan Li, Zheng Li
Tao Ren, Jia-Hui Guan, Department of Colorectal Surgery, Taihe County People’s Hospital of Anhui Province, Fuyang 236600, Anhui Province, China
Yu Li, Department of Pharmacy, Taihe County People’s Hospital of Anhui Province, Fuyang 236600, Anhui Province, China
Nan-Nan Li, University of Science and Technology of China, The First Affiliated Hospital of University of Science and Technology of China, Hefei 230001, Anhui Province, China
Zheng Li, Jiangsu Engineering Research Center of Cardiovascular Drugs Targeting Endothelial Cells, College of Health Sciences, School of Life Sciences, Jiangsu Normal University, Xuzhou 221116, Jiangsu Province, China
Author contributions: Ren T acquisition, analysis and interpretation of data, drafting the article, final approval; Guan JH, Li Y, Li NN analysis and interpretation of data, final approval; Li Z conception and design of the study, critical revision, and final approval.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zheng Li, PhD, Pharmacist, Jiangsu Engineering Research Center of Cardiovascular Drugs Targeting Endothelial Cells, College of Health Sciences, School of Life Sciences, Jiangsu Normal University, No. 101 Shanghai Road, Xuzhou 221116, Jiangsu Province, China. lizhengcpu@163.com
Received: March 27, 2024
Revised: July 27, 2024
Accepted: August 19, 2024
Published online: September 18, 2024
Processing time: 169 Days and 10.9 Hours
Core Tip

Core Tip: In past decades, the pharmacological treatments for juvenile idiopathic arthritis (JIA) have undergone a dramatic evolution from non-steroidal anti-inflammatory drugs to disease-modifying antirheumatic drugs (DMARDs), especially the emergence of biologic DMARDs enable patients with refractory JIA to achieve disease remission. This editorial focuses on the progress in treatment options for JIA. We hope that this editorial could provide valuable information for use of anti-JIA drugs.